Infarction: Events and Recovery (PREMIER) study, which was used to externally validate the models. 6 Both registries used identical inclusion and exclusion criteria and were coordinated by the Saint Luke's Mid America Heart Institute. To be eligible for either registry, patients were required to have biomarker evidence of myocardial necrosis and additional clinical evidence supporting the diagnosis of an AMI, including prolonged ischemic signs/symptoms (≥20 minutes) or electrocardiographic ST changes during the initial 24 hours of admission.
Baseline data were obtained through chart abstraction and a structured interview by trained research staff within 24 to 72 hours of admission. Consenting patients had fasting blood specimens collected before discharge. Fasting blood was drawn from each subject, which was processed, refrigerated, and sent by overnight mail to the core laboratory (Clinical Reference Laboratory, Lenexa, KS) on a daily basis. Blood was analyzed for glucose, glycated hemoglobin (HbA1c), and lipid levels. Chart data on laboratory values drawn for clinical purposes were also recorded, which included up to 3 fasting plasma glucose levels and a random plasma glucose on admission. Each participating hospital obtained Institutional Research Board approval, and all patients provided written informed consent for baseline and follow-up assessments. Spanish-speaking patients were provided with translations of informed consent documents and interviews, which were conducted by Spanish-speaking staff or medical interpreters.
DM Diagnoses
Both patients with known DM and with incident DM (ie, diagnosed during the AMI) were included. Known DM was defined as patients with a chart-documented diagnosis of DM or those on glucose-lowering medications at the time of admission (except for metformin or thiazolidinedione used as monotherapy without a documented DM diagnosis, as these may be used for DM prevention [n=2 patients]). Incident DM was defined as HbA1c ≥6.5% by core laboratory or chart abstraction. If HbA1c level was missing, DM could be additionally diagnosed as (1) ≥2 fasting blood glucose levels ≥126 mg/dL or (2) ≥1 fasting blood glucose ≥126 mg/dL and random blood glucose (at presentation) ≥200 mg/dL. 7
Outcomes Assessment
Detailed follow-up interviews were attempted on all patients at 1 month, 6 months, and 1 year after AMI. Mortality was assessed through a combination of follow-up interviews (through 1 year) and a query of the Social Security Death Masterfile. Angina and disease-specific health status was assessed using the Seattle Angina Questionnaire (SAQ) 8 during each follow-up interview after AMI. The SAQ is a reliable and valid 19-item questionnaire that comprises 5 clinically important domains in patients with coronary artery disease. The scores for all SAQ domains range from 0 to 100, with higher scores indicating less disease burden. For the outcome of this study, we focused on the SAQ angina frequency domain (categorized as none versus any [score 100 versus <100]). 9
Statistical Analysis
We constructed 2 models: (1) a Cox proportional hazards model for time to death of any cause for 5 years and (2) a logistic regression model for prevalence of angina (SAQ Angina Frequency score <100) at the 1-year assessment. Using clinical judgment, we selected candidate predictors available at the time of the AMI hospitalization from larger conceptual domains: demographics, socioeconomics, lifestyle, medical comorbidities, health status at the time of AMI, clinical status at presentation, treatments during AMI hospitalization, and metabolic factors (full candidate variable list is available in the Table I in the Data Supplement). We avoided including highly correlated variables, and collinearity diagnostics on the selected variables were excellent (condition index=3.0, largest variance inflation factor=1.8). These variables comprised 30 total degrees of freedom, which was within the 10 to 20 events/degrees of freedom threshold for minimizing the risk of overfitting for mortality (436 events) but exceeded the threshold for angina (263 events). We therefore evaluated the potential for overfitting using bootstrap validation of the model calibration slopes of observed versus predicted outcomes. The calibration slope is always equal to 1 in the data on which the model was fit, but will be <1 on subsequent data sets if overfitting is present. The bootstrapped calibration slopes were 0.92 for mortality but 0.86 for angina, suggesting moderate overfitting in the latter model. To correct for this, we used penalized maximum likelihood estimation, which shrinks parameter estimates to account for overfitting with the goal of improved predictive accuracy in future data. 10 Because of the constraints on model degrees of freedom, continuous variables were entered as linear effects to avoid further increasing the risk of overfitting. We assessed the potential for misspecification by adding nonlinear terms for all continuous variables using 3-knot restricted cubic splines and conducting a global test for any nonlinearity. This test was nonsignificant for the angina model (P=0.98) but significant for mortality (P=0.04) because of a strong nonlinear association with admission creatinine (P=0.001). However, the association with log creatinine was linear (P=0.33), so creatinine was log-transformed for the analyses. No other effects deviated from linearity. We also conducted a global test of the proportional hazards assumption for the mortality model, which was nonsignificant (P=0.51). Harrell's backward selection strategy was used to select a parsimonious set of variables for a simplified prediction tool. 11 The contribution of each covariate to the predicted values from the full model was ranked by F value, and variables with the smallest contribution were sequentially eliminated until further variable elimination led to a >5% loss in model prediction, as compared with the full model. The remaining covariates comprised the parsimonious model and explained >95% of the variance of the full model. The performance of the reduced model (model discrimination and predicted risks) was compared with the full model to ensure that variable elimination did not degrade model performance.
Approximately 31% of patients had missing data for various predictor variables; the highest missing rate for any 1 variable was 10% (hemoglobin A1c) and only 8% of patients were missing data on >1 variable. In addition, 30% of patients who were alive at 1 year after AMI were missing 1-year angina assessments because of incomplete followup. However, ≈60% of these patients had assessments at either 1 or 6 months (or both), which were fairly strongly correlated with 1-year assessments (r=0.41 and 0.50, respectively). We used multiple imputation
WHAT IS KNOWN
• Patients with diabetes mellitus experience a higher rate of death and recurrent ischemia after myocardial infarction compared with patients without diabetes mellitus. • Patients with diabetes mellitus are not a homogeneous group, and differences among these patients in demographics, clinical factors, and metabolism could markedly alter the risks of individual patients.
WHAT THE STUDY ADDS
• We developed and externally validated models for long-term mortality and angina after myocardial infarction among patients with diabetes mellitus. • Although patients with diabetes mellitus are at higher risk of adverse events on average, these models were able to separate patients with diabetes mellitus into groups with low and high risks of these 2 outcomes. • Use of these models at the time of hospital discharge after myocardial infarction may permit identification of patients who may benefit from closer follow-up and more intensive secondary prevention strategies.
to account for missing predictor values and 1-year angina scores, using sequential regression imputation on all available covariates and outcome variables as well as 1-and 6-month angina scores. 12 Model development was repeated on each of the 50 imputed data sets, and final model estimates were obtained by pooling across data sets. Missing angina assessments because of death (10% of patients) was not imputed; results for the angina model are conditional on survival through 1 year. Survival status through 5 years was obtained on 100% of patients.
Internal validation of c-statistics and calibration curves for both the full and reduced models was conducted using bootstrap methods: the above modeling process was repeated on each of 100 bootstrap samples, and optimism in model performance was calculated as the difference between apparent performance (on the bootstrapped data set) and honest performance from applying the model to the original data set. The average optimism over all replications was calculated and subtracted from the original model performance. In addition, models were also validated externally using an independent data set (PREMIER). When we used the coefficient estimates from the TRIUMPH prediction model to calculate the predicted risk of angina in PREMIER, the intercept for the model was recentered using the global mean for risk of angina for PREMIER, congruent with approaches used to risk-standardize 30-day outcomes by the Center for Medicare and Medicaid Services. 1, 13 Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.2.1, 14 and statistical significance was determined by a 2-sided P value of <0.05.
Results

Study Population
Among 4340 patients enrolled in TRIUMPH, 1,626 were confirmed as having DM (2567 did not have DM and 147 had insufficient data to determine DM status). Of these, 13 patients died in-hospital, leaving 1613 patients in the primary cohort for these analyses. There were 143 patients who died before 1 year and were therefore ineligible to be in the angina cohort. Among 1470 surviving patients, 976 (66%) had a 1-year angina assessment, 285 (19%) had an angina assessment at 1 or 6 months, and 209 (14%) were lost to follow-up (all surviving patients were included in the angina cohort, using multiply imputed scores for those missing angina assessments). The demographic, clinical, and treatment characteristics of the 2 analytic cohorts are shown in Table 1 . Mean age of the population was 60 years, 60% were men, 58% were white, and 
Mortality Model
The Kaplan-Meier estimated rate of mortality among patients with DM discharged alive was 8.9% at 1 year and 27.1% at 5 years. Estimated predictor effects from the full model are shown in Table 2 . The most important predictors (in terms of χ 2 value) of long-term mortality after AMI were higher serum creatinine (hazard ratio, 1.27 per 50% increase; 95% confidence interval [CI], 1.18-1.36), not working at the time of the AMI (hazard ratio, 1.95; 95% CI, 1.47-2.58), older age (hazard ratio, 1.29 per 10 years; 95% CI, 1.16-1.44), and lower admission hemoglobin (hazard ratio, 0.90 per 1 g/dL increase; 95% CI, 0.85-0.94). The global test for any deviation from the proportional hazards assumption for 5 years was nonsignificant (P=0.51), indicating that the effect of patient characteristics on mortality risk does not change appreciably between 1 and 5 years. The simplified model demonstrated good discrimination (c-index=0.79; bootstrap validated 0.78) and excellent calibration ( Figure 1A) . The lowest decile of predicted risk had a 5-year mortality event rate of 4%, whereas 80% of the patients in the highest decile of predicted risk died at 5 years. The simplified model with integer scoring and risk categorization is shown in Table III in the Data Supplement. Among patients with DM in PREMIER, the model continued to demonstrate good discrimination (c-index=0.78) and excellent calibration ( Figure 1B ).
Angina Model
At 1 year after AMI, 27.0% of patients with DM reported having angina. The variables included in the final model are shown in Table 3 . The most important predictor of angina after AMI (in terms of χ 2 value) was the burden of angina present before the AMI (odds ratio, 1.18 per 10 point decrease in baseline SAQ Angina Frequency score; 95% CI, 1.11-1.26). Other important predictors of having angina at 1 year after the AMI were younger age (odds ratio, 0.79 per 10 year increase; 95% CI, 0.60-0.90) and a history of prior coronary bypass graft surgery (odds ratio, 1.67; 95% CI, 1. 16-2.40 ). The simplified model demonstrated moderate discrimination (c-index=0.71; bootstrap validated 0.69) and excellent calibration (Figure 2A) . Twelve percent of the patients in the lowest decile of risk reported angina at 1 year, compared with 59% of patients in the highest decile of risk. The simplified model with integer scoring and risk categorization is shown in Table IV in the Data Supplement. Among patients with DM in PREMIER, the model continued to demonstrate moderate discrimination (c-index=0.73) and excellent calibration ( Figure 2B ).
Discussion
Because of the rising prevalence of DM among patients admitted with an AMI, which is now ≈40%, 15 understanding the effect of DM on outcomes after an AMI is becoming increasingly important. Patients with DM have long been known to be at high risk for morbidity and mortality after an AMI, 2,3 in part, because of more extensive coronary artery disease, 16 additional cardiovascular risk factors, and higher burden of comorbidities. In our analyses, we were able to build and externally validate prediction models to identify patients with DM who are at particularly high risk of post-AMI morbidity and mortality. The use of these models at the time of hospital discharge after AMI may permit identification of patients with DM and AMI for whom closer follow-up and more intensive secondary prevention strategies may be warranted, including careful discharge education and counseling provided for patients and their families.
DM-Specific Predictors
Interestingly, although we identified several unique predictors for poor outcomes among patients with AMI with DM that are not in traditional risk models (eg, not used at time of AMI, low hemoglobin, low activity during leisure time), 17 most of these predictors were not specific to the underlying DM. Specifically, HbA1c level was not a significant predictor for either of the outcomes studied. In the mortality models, the use of insulin before admission (often considered a proxy for longer duration of DM and worse glycemic control) was associated with increased risk of death but not subsequent angina. For angina, there were no DM-specific predictors in the reduced model. However, there were some predictors of angina among patients with DM that had not been identified in prior models examining predictors of angina after AMI. For example, chronic heart failure has not been identified as a predictor of 1-month angina among all patients with AMI 18 or 6-month angina among all patients after percutaneous coronary intervention. 19 Although the time frame of analysis may partially explain this finding, it may also be that patients with DM and heart failure, in combination (a growing and highrisk patient group), are more likely to have residual angina after AMI. Furthermore, we found that certain factors that had been predictive of poor outcomes in models including all patients with AMI, such as peak troponin, were not identified as significant predictors among only patients with DM. Other identified predictors of angina among patients with DM-such as depression, younger age, prior bypass graft surgery, smoking, and lower socioeconomic status 18-21 -and of mortality among patients with DM-older age, renal dysfunction, anemia, heart failure, prior AMI, and low body weight 22-24 -are consistent with prior studies in patients with and without DM.
Clinical Implications
Patients with DM who are hospitalized with an AMI are typically considered high risk for subsequent ischemic outcomes. However, our findings suggest that there is a wide distribution of risk in this patient population. For example, the overall 5-year mortality rate was 27%; however, 30% of the patients had a predicted risk of mortality of <10%, whereas 16% of the population had a 5-year risk of death of >50%. Similar relationships were observed for angina. Given this broad distribution of risk among those with DM and AMI, our risk models would allow for better identification of patients' risk so that follow-up and treatment strategies can be triaged and allocated accordingly, rather than just on the basis of having DM. Individualized risk-stratification at the time of discharge may allow better-informed counseling for patients and families and a more objective approach to earlier versus later follow-up after hospital discharge. Given the fact that angina is a powerful driver of repeat hospitalizations and healthcare costs, 25 such an approach is especially relevant in the era when hospitals are under increased scrutiny to reduce hospital readmissions after AMI.
Furthermore, although some treatments during and after an AMI should be applied to all patients-such as intensive statins and cardiac rehabilitation-there remain other therapies that may be selected in the case of higher risk features. For example, the risk-benefit ratio for prasugrel or ticagrelor may be more favorable in patients at higher ischemic risk and could be targeted to patients at high risk for post-AMI mortality. In addition, staged revascularization of nonculprit coronary arteries or adjunctive antianginal therapies may be useful in patients at high risk for angina after AMI. As these treatments are associated with higher costs, targeting them in the higher risk patients may be an effective and efficient strategy for improving outcomes in patients with DM and AMI. Whether such an approach can improve patient outcomes and reduce costs remains to be determined and should be evaluated in future studies.
Limitations
There are potential limitations to our study that merit further discussion. The discrimination of our models was moderate with c-index ranges of ≈0.7 to 0.8. Although this performance is similar or better than most existing prediction models in the general AMI population, 22, 26 further exploration to identify factors that contain incremental prognostic information, such as genetic factors or more detailed metabolic factors, will be important to improve these models over time. Second, given the number of events in our analytic population, we had to limit our number of candidate variables to avoid overfitting. In addition, we explicitly accepted overfitting for the angina model (which we subsequently corrected for) to examine a broader number of candidate variables. As such, it is possible that there were some predictors that we did not consider. Third, missing data, both predictor and outcomes (angina), could have influenced our results. However, our inclusion of a broad range of predictors and the use of multiple imputation, including 1-and 6-month angina assessments in the imputation model, mitigate selection biases associated with observed factors and appropriately adjust statistical inferences to account for uncertainty because of missingness. Finally, patients who died before 1 year were not included in the angina model, potentially introducing a survival bias in this analysis. Importantly, these 2 models should be used to inform patients in combination, to estimate risk of long-term mortality and (if alive) risk of angina.
Conclusions
In 2 large multicenter AMI registries, we built and validated models for predicting long-term outcomes specifically among patients with AMI with DM. We demonstrated that although patients with DM and AMI are high risk on average, there was a wide distribution of risk within this population, with some patients being at extremely high risk for adverse events during follow-up, whereas others being at low risk. Our models could be used for an individualized approach to risk-stratification at the time of discharge and identification of patients for whom closer follow-up and secondary prevention strategies can be targeted most aggressively. design of the study, the interpretation of the analyses, and writing of the article. The decision to submit the article for publication was made independent of the study sponsor. 
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